Bausch + Lomb Launches R&D “Teach-In” Webinar Series

Key Takeaways

• Webinar showcases ELios laser glaucoma surgery, EU launch done
• BL1107 aims to treat vision loss, not just pressure
• U.S. launch of ELios expected H2 2026
• Executive team including CEO will field investor questions
• Replay available on investor relations site after event

Summary

Bausch + Lomb announced the kickoff of an R&D “Teach‑in” webinar series, beginning with a March 23 session focused on its glaucoma pipeline. Executive Vice President of R&D Yehia Hashad and senior leaders will discuss ELios™, an implant‑free laser glaucoma surgery already launched in Europe, and BL1107, a novel drug targeting both intra‑ocular pressure and vision loss. The live event, hosted by Wells Fargo, will be streamed to investors and later posted on the company’s IR site. The series aims to deepen stakeholder insight into Bausch + Lomb’s differentiated eye‑health innovations.

Pulse Analysis

Bausch + Lomb’s new R&D "Teach‑in" webinar series reflects a broader industry trend toward greater transparency around product pipelines. By inviting investors and analysts into a live discussion with senior scientists and executives, the company not only demystifies its research process but also builds credibility in a market where innovation cycles are increasingly scrutinized. The format, supported by Wells Fargo’s Innovation Spotlight, positions Bausch + Lomb as a thought leader willing to share data‑driven insights, a strategy that can enhance shareholder confidence and attract strategic partners.

The spotlight on ELios™ and BL1107 underscores Bausch + Lomb’s dual approach to glaucoma—a condition affecting over 70 million people worldwide. ELios, an implant‑free, excimer‑laser procedure, aligns with the shift toward minimally invasive glaucoma surgeries (MIGS) that promise quicker recovery and fewer complications compared to traditional trabeculectomy. Its European commercialization provides a real‑world performance benchmark ahead of the anticipated U.S. launch in the second half of 2026. Meanwhile, BL1107 aims to be the first therapy that simultaneously lowers intra‑ocular pressure and addresses progressive vision loss, potentially expanding the addressable market beyond pressure‑only treatments and differentiating Bausch + Lomb from competitors focused solely on IOP reduction.

For investors, the webinar offers a rare glimpse into development timelines, regulatory pathways, and commercial strategies. The involvement of the CEO and CFO signals that these assets are central to the company’s growth narrative, likely influencing future earnings forecasts. As the eye‑care sector faces mounting pressure from generic competition and reimbursement challenges, Bausch + Lomb’s pipeline diversification could provide a defensive moat. Stakeholders should monitor the upcoming U.S. launch milestones and any data releases from ongoing clinical trials, as these will be key catalysts for the stock’s performance in the coming years.